Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse

Myelodysplastic Syndromes (MDS) Clinical Trial

Official title:

A Single Arm Phase II Trial of Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01995578
• Other study ID #: 13-192
• Status: Completed
• Phase: Phase 2
• Start date: December 2013
• Est. completion date: September 27, 2023

Study information

• Verified date: September 2023
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to learn if 5'-Azacitidine will help to lower the risk of the disease coming back after a stem cell transplant in patients with MDS and AML. This study will also be looking at the side effects of this medicine. 5'-Azacitidine is an FDA approved drug for treatment of MDS and AML, as well as patients whose disease came back after transplant, where it helped going into remission. It is unclear if 5'-Azacitidine can prevent the disease from coming back after transplant. This study will help show if getting 5'-Azacitidine soon after transplant can lower the risk of your disease coming back.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: September 27, 2023
• Est. primary completion date: September 27, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 75 Years

Eligibility

Inclusion Criteria:

Patients who have undergone T cell depleted allogeneic hematopoietic stem cell

transplantation at MSKCC for:

• De novo myelodysplastic syndromes (MDS): IPSS-1 with poor risk cytogenetics or higher IPSS.
• Acute myelogenous leukemia (AML) in first remission that required more than 1 cycle of treatment to achieve remission or with the following cytogenetic abnormalities: FLT3 mutation, deletion/monosomy of chromosome 5 or 7, MLL gene rearrangement, or more than or equal to 3 cytogenetics abnormalities. Also patients in second or greater remission.
• Patients with Secondary MDS/AML.
• Patients will be considered eligible for the study if after transplant they achieved hematologic (<5% blasts) and cytogenetic remission.
• Patients will be eligible to enter the study between 60-120 days post transplant.
• Age: pediatrics and adults patients - 1 year old-75 years old.
• Karnofsky performance status >=60% for patients >16yo and Lansky performance status >=60% for patients =16yo
• Stable blood counts (ANC>1000/uL, Hb>8gr/dL, Plt>50,000/ uL) not supported by transfusions.
• Renal: Serum creatinine <1.5 ULN
• Hepatic: <3xULN ALT and <1.5 total serum bilirubin, unless there is congenital benign hyperbilirubinemia.
• Cardiac: Adequate cardiac function measured by LVEF>50%. If asymptomatic, pretransplant echocardiogram is adequate. If symptomatic, echocardiogram needs to be repeated.
• Each patient must be willing to participate as a research subject and must sign an informed consent form. Exclusion Criteria:

Patients will be excluded from the trial if at time of enrollment:

• Active uncontrolled bacterial, fungal or viral infection.
• Evidence of uncontrolled graft-versus-host disease.
• Pulmonary: new onset hypoxia
• Known or suspected hypersensitivity to 5'-azacitadine or mannitol.
• Evidence of residual disease either by increased blasts count (>5%) or persistence of previous known cytogenetics abnormalities.
• Peripheral blood neutrophil chimerism: less than 95% donor.

Related Conditions & MeSH terms

• Acute Myelogenous Leukemia (AML)
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Myelodysplastic Syndromes
• Myelodysplastic Syndromes (MDS)
• Preleukemia
• Syndrome

Intervention

Drug:
• low dose 5'-azacitidine
5'-azacitadine will be given at a low dose of 32mg/m2 S.C for 5 days every 28 days (a cycle). Dose de-escalation will be permitted for hematologic and non- hematologic toxicities. Patients will start taking the study drug between days 60-120 post TCD allogeneic hematopoietic stem cell transplant and up to a year post-transplant or until there is a toxicity that requires cessation of therapy. Therefore patients will get between 8-10 cycles. Patients who come off-study for reasons unrelated to toxicities before completing 4 cycles will be replaced Since most cases of relapse occur early post transplant, in the first year, this is the most appropriate time to intervene. Treatment will start as soon as possible.

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering at Basking Ridge (Consent and Follow-up)	Basking Ridge	New Jersey
United States	Memorial Sloan Kettering Commack (Consent and Follow-up)	Commack	New York
United States	Memorial Sloan Kettering Westchester (Consent and Follow-up)	Harrison	New York
United States	Memorial Sloan Kettering Monmouth (Consent and Follow-up)	Middletown	New Jersey
United States	Memorial Sloan Kettering Bergen (Consent and Follow-up)	Montvale	New Jersey
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	Memorial Sloan Kettering Nassau (Consent and Follow-up)	Rockville Centre	New York

Sponsors (1)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Relapse Rate	Relapse of MDS or AML will be analyzed as to type and genetic origin of the leukemic cells. These will be defined by morphologic and/or cytogenetic criteria: an increasing number of blasts in the marrow over 5%, by presence of circulating blasts, or by presence of blasts in any extramedullary site as well as presence of previous cytogenetic abnormalities. Other studies assessing for MRD, FACS and FISH assays will be evaluated but would not be considered disease relapse if positive since they are experimental.	2 years
Secondary	Overall Survival	Kaplan-Meier methodology will be used to compare overall survival.	2 years
Secondary	Number of Participants Evaluated for Treatment Safety	The safety will be described by tabulating the number of transfusions, frequencies of bleeding and serious infections, and the use of G-CSF support.	2 years

External Links

•   Memorial Sloan Kettering Cancer Center